MXPA01005562A - Anticuerpos y fragmentos de anticuerpos modificados con mayor duracion de actividad. - Google Patents

Anticuerpos y fragmentos de anticuerpos modificados con mayor duracion de actividad.

Info

Publication number
MXPA01005562A
MXPA01005562A MXPA01005562A MXPA01005562A MXPA01005562A MX PA01005562 A MXPA01005562 A MX PA01005562A MX PA01005562 A MXPA01005562 A MX PA01005562A MX PA01005562 A MXPA01005562 A MX PA01005562A MX PA01005562 A MXPA01005562 A MX PA01005562A
Authority
MX
Mexico
Prior art keywords
group
antibodies
human
modified antibodies
activity
Prior art date
Application number
MXPA01005562A
Other languages
English (en)
Inventor
George A Heavner
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of MXPA01005562A publication Critical patent/MXPA01005562A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA01005562A 1998-11-03 1999-11-02 Anticuerpos y fragmentos de anticuerpos modificados con mayor duracion de actividad. MXPA01005562A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18515198A 1998-11-03 1998-11-03
PCT/US1999/025790 WO2000026256A2 (en) 1998-11-03 1999-11-02 Modified antibodies and antibody fragments with increased duration of activity

Publications (1)

Publication Number Publication Date
MXPA01005562A true MXPA01005562A (es) 2003-08-01

Family

ID=22679823

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01005562A MXPA01005562A (es) 1998-11-03 1999-11-02 Anticuerpos y fragmentos de anticuerpos modificados con mayor duracion de actividad.

Country Status (13)

Country Link
EP (1) EP1144452B1 (es)
CN (1) CN1406138A (es)
AT (1) ATE315410T1 (es)
AU (1) AU768295B2 (es)
CA (1) CA2353082A1 (es)
CY (1) CY1105333T1 (es)
DE (1) DE69929467T2 (es)
DK (1) DK1144452T3 (es)
ES (1) ES2257094T3 (es)
MX (1) MXPA01005562A (es)
NZ (1) NZ512055A (es)
PT (1) PT1144452E (es)
WO (1) WO2000026256A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
EP2184606B1 (en) * 2008-11-03 2015-06-24 Helena Laboratories (UK) Ltd. Immunodisplacement Electrophoresis
EA030827B1 (ru) 2009-10-23 2018-10-31 Милленниум Фармасьютикалз, Инк. Анти-gcc антитело и его применения
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
CN104768975A (zh) * 2012-08-31 2015-07-08 北卡罗来纳大学教堂山分校 用于增强或抑制胰岛素-样生长因子1(igf-1)的单克隆抗体
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
US10647777B2 (en) * 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
EP3684414A4 (en) * 2017-09-19 2021-06-09 Immunwork Inc. PHARMACEUTICAL CONSTRUCTIONS WITH IMPROVED BINDING AFFINITY WITH ALBUMIN
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
KR20230146032A (ko) 2021-02-15 2023-10-18 다케다 야쿠힌 고교 가부시키가이샤 Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006133A1 (en) * 1988-11-25 1990-06-14 Centocor, Inc. Heterobifunctional antibodies having specificity for platelets and thrombolytic agents
DE69020548T2 (de) * 1989-04-03 1996-03-07 Centocor Inc Blutplättchenspezifische immunokonjugate.
CN1186439A (zh) * 1995-06-07 1998-07-01 森特克公司 血小板特异性的嵌合性免疫球蛋白及其使用方法
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
ATE200030T1 (de) * 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
JP2001512480A (ja) * 1997-02-19 2001-08-21 セントコア，インコーポレイテッド 持続的薬物送達およびそれに有用な組成物
CA2288994C (en) * 1997-04-30 2011-07-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides

Also Published As

Publication number Publication date
WO2000026256A2 (en) 2000-05-11
EP1144452A3 (en) 2002-03-13
DK1144452T3 (da) 2006-05-29
WO2000026256A9 (en) 2002-08-22
NZ512055A (en) 2003-11-28
WO2000026256A3 (en) 2001-11-08
EP1144452A2 (en) 2001-10-17
CY1105333T1 (el) 2010-03-03
ES2257094T3 (es) 2006-07-16
PT1144452E (pt) 2006-05-31
EP1144452B1 (en) 2006-01-11
DE69929467T2 (de) 2006-09-28
AU1907800A (en) 2000-05-22
DE69929467D1 (de) 2006-04-06
CN1406138A (zh) 2003-03-26
ATE315410T1 (de) 2006-02-15
AU768295B2 (en) 2003-12-04
CA2353082A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
MXPA01005562A (es) Anticuerpos y fragmentos de anticuerpos modificados con mayor duracion de actividad.
Stockwell Biology of cartilage cells
Matsiko et al. Advanced strategies for articular cartilage defect repair
Funakoshi et al. Application of tissue engineering techniques for rotator cuff regeneration using a chitosan-based hyaluronan hybrid fiber scaffold
Wu et al. Studies on the microspheres comprised of reconstituted collagen and hydroxyapatite
Muzykantov et al. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs
Huang et al. The modulation of endothelial cell morphology, function, and survival using anisotropic nanofibrillar collagen scaffolds
DE69128791T2 (de) Modifizierte antikörper mit kontrollierter clearance-zeit
BR9813202A (pt) Processo de administração de genes a células da pele que apresentam antìgenos
ID28595A (id) Bahan pembawa termodifikasi, katalisoksida kompleks dan proses pembuatan asam akrilat
KR900701302A (ko) 암치료를 위한 신규의 고친화성 변형된 항체군
FR2794477B1 (fr) Cable de structure d'ouvrage de construction, troncon de gaine d'un tel cable, et procede de pose
McClurg et al. Targeting cartilage degradation in osteoarthritis
EP2298310A3 (en) Therapeutic inhibitors of vascular smooth muscle cells
FR2763943B1 (fr) Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
Saad et al. Biodegradable polymeric materials
Filová et al. Hydrogel containing anti-CD44-labeled microparticles, guide bone tissue formation in osteochondral defects in rabbits
Haidarliu et al. Collagenous skeleton of the rat mystacial pad
JPS57117868A (en) Method of combining biological active substance to carrier containing hydroxyl group
DE69416601D1 (de) Verwendung von antiidiotypischen antikörpern zur vorbeugung einer hyperakuten abstossung von xenotransplantaten
DE69428278T2 (de) Leukozytadhaesiontest
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
Krishnaveni et al. Preamble to Biomaterials and its Applications in Science and Technology
Rudert et al. Bioartificial cartilage
Jun et al. Ethanol‐dispersed polymer nanofibers as a highly selective cell isolation and release platform for CD4+ T lymphocytes